This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Chemours Company (CC) Receives a Buy from RBC Capital

Tipranks - Tipranks - Thu Feb 26, 12:52AM CST

RBC Capital analyst Arun Viswanathan maintained a Buy rating on Chemours Company on February 23 and set a price target of $21.00. The company’s shares closed yesterday at $18.03.

Claim 50% Off TipRanks Premium

According to TipRanks, Viswanathan is a 4-star analyst with an average return of 3.5% and a 57.20% success rate. Viswanathan covers the Basic Materials sector, focusing on stocks such as Dow Inc, Albemarle, and Celanese.

In addition to RBC Capital, Chemours Company also received a Buy from UBS’s Joshua Spector in a report issued on February 23. However, on the same day, Morgan Stanley maintained a Hold rating on Chemours Company (NYSE: CC).

See Insiders’ Hot Stocks on TipRanks >>

Based on Chemours Company’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.33 billion and a GAAP net loss of $61 million. In comparison, last year the company earned a revenue of $1.39 billion and had a GAAP net loss of $8 million

Read More on CC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).